Kidney cancer study tests best order of targeted drugs
NCT ID NCT01217931
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study looks at 180 people with kidney cancer that has spread. It compares six different ways to give two drugs (everolimus, bevacizumab, or pazopanib) one after the other. The goal is to see which sequence works best and is safest for controlling the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Could an ALS drug clear the fog of chemo brain?
- Ancient Mind-Body practice tested as fatigue fighter for men after cancer
- Can a website help cancer survivors live healthier? large study tests online lifestyle coaching
- Drug that starves tumors shows promise against advanced kidney cancer
- Could a common bile acid pill shield kidneys during cancer surgery?